A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer
A Phase 1 Study of a Second Psilocybin Group Retreat for Partial Responders With Anxiety Associated With Metastatic Cancer
Sponsor: Steven & Alexandra Cohen Foundation
A PHASE1 clinical study on Hematopoietic and Lymphatic System Neoplasm and Metastatic Malignant Solid Neoplasm, this trial is completed. The trial is conducted by Steven & Alexandra Cohen Foundation and has accumulated 6 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jul 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2025 — Jul 2025 [monthly]
Recruiting PHASE1
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE1
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Nov 2024 — Dec 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Steven & Alexandra Cohen Foundation
- University of Washington
For direct contact, visit the study record on ClinicalTrials.gov .